Publications

Publications

New lessons from an old gene: complex splicing and a novel cryptic-exon in VHL gene cause erythrocytosis and Von Hippel Lindau disease
Lenglet M., Robriquet F., Schwarz K., Carme C., Couturier A., Hoogewijs D., Buffet A ., Knight S., Gad S., Couvé .S., Chesnel F., Pacault M., Lindenbaum P., Job S., Dumont S., Besnard T., Cornec M., Deveaux S., Burnichon N., Ferlicot S., Vilaine M., Mazzella JM., Airaud F., Garrec C., Heidet L., Irtan S., Mantadakis E., Bouchireb K., Debatin KM., Redon R., Bezieau S., Bressac-de Paillerets B., Teh Bin T., Girodon F., Randi ML., Putti MC., Bours V., Van Wijk R., Göthert J., Kattamis A., Janin N., Bento C., Taylor JC., Arlot-Bonnemains Y., Richard S., Gimenez-Roqueplo AP., Cario H., Gardie B. . 
Blood  2018 accepted for publication 

Biocompatible nanoparticles containing hydrophobic nickel-bis(dithiolene) complexes for NIR-mediated doxorubicin release and photothermal therapy
Ciancone, M; Mebrouk, K; Bellec, N; Le Goff-Gaillard, C; Arlot-Bonnemains Y; Benvegnu, T; Fourmigue, M; Camerel, F; Cammas-Marion, S.
Journal of Materials Chemistry B, 2018

Fine and Clean Photothermally-Controlled NIR Drug Delivery from Biocompatible Nickel-bis(dithiolene) Containing Liposomes
K Mebrouk, M Ciancone, T Vives, S Cammas-Marion, Ty Benvegnu, C Le Goff-Gaillard, Y Arlot-Bonnemains, M Fourmigué and F Camerel  
Chem Com   2017

The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13
P Hascoet ,  F Chesnel, F Jouan , C Le Goff , A Couturier, E Darrigrand , F Mahé , N Rioux-Leclercq ,  X Le Goff , Y Arlot-Bonnemains  
Oncotarget  2017 June

Deregulated expression of VHL mRNA variants in papillary thyroid cancer
Baldini E, ,Tucilli C Arlot-Bonnemains  Y Chesnel, F, Sorrenti S, De Vito C, Catania A, D’Arminento e, Entonelli A, Fallahi P, Watutantrige S, Tartaglia F, Barollo S Mian C, Bononi M, Arceri,S, Mascagni D, Vergine M, Pironi D, Monti M, Fillipini A, Ulisse SW
Mol  Cell Endocrinol  2017 Mar

Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer.
Tuccilli C, Baldini E, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, D'Armiento E, Antonelli A, Fallahi P, Watutantrige S, Tartaglia F, Barollo S, Mian C, Arcieri S, Mascagni D, Pironi D, Bononi M, Vergine M, Monti M, Filippini A, Ulisse S.
​Int J Oncol. 2017 Mar 

SHIP2 regulates lumen generation, cell division and ciliogenesis through the control of basolateral to apical lumen localization of Aurora A and HEF 1
O Hamze Komaiha, S Sarr Y Arlot-Bonnemains , DSamuel, and A Gassama-Diagne 1
Cell Reports   2016 Dec  

Aggregation dynamics and identification of aggregation-prone mutants of the von Hippel-Lindau tumor suppressor protein
Le Goff X, Chesnel F, Delalande O, Couturier A, Derano S, Le Goff C, Vigneau C, Arlot-Bonnemains Y
J.Cell. Sci. 2016 Jun

Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis
Hascoet P, Chesnel F, Le Goff C, Le Goff X, Arlot-Bonnemains Y.
Front Oncol. 2015 Oct 

The Von Hippel Lindau tumor suppressor gene: Uncovering the expression of the pVHL172
Chesnel F, Hascoet P, GagneJP, Couturier A,  Jouan F, Poirier G, Le Goff C, Vigneau C, Danger Y, Verite F , Le Goff X, & Arlot-Bonnemains Y.
Br J Cancer. 2015 Jun

Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival
Dagher J, Dugay F, Rioux-Leclercq N, Verhoest G, Oger E, Bensalah K, Cabillic F, Jouan F, Kammerer-Jacquet SF, Fergelot P, Vigneau C, Arlot-Bonnemains Y, Belaud-Rotureau MA.
Hum Pathol. 2014 Aug

Histologic prognostic factors associated with chromosomal imbalances in a contemporary series of 89 clear cell renal cell carcinomas 
Dagher J, Dugay F, Verhoest G, Cabillic F, Jaillard S, Henry C, Arlot-Bonnemains Y, Bensalah K, Oger E, Vigneau C, Rioux-Leclercq N, Belaud-Rotureau MA.
Hum Pathol. 2013 Oct

Water-soluble nickel-bis(dithiolene) complexes as photothermal agents 
Mebrouk K, Chotard F, Le Goff-Gaillard C, Arlot-Bonnemains Y, Fourmigué M, Camerel  F. 
Chem Commun (Camb). 2014 Nov

Renin-angiotensin system and urological cancers
Verhoest G, Dolley-Hitze T, Jouan F, Bensalah K, Arlot-Bonnemains Y, Dugay F, Belaud-Rotureau MA, Rioux-Leclercq N, Vigneau C
Prog Urol. 2014 Feb

Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis
Dugay F, Le Goff X, Rioux-Leclerq N, Chesnel F, Jouan F, Henry C, Cabillic F, Verhoest G, Vigneau C, Belaud-Rotureau MA and Arlot-Bonnemains Y. (YAB And MABR are co-last authors YAB is the correpsonding  author)
Int J Cancer. 2014 May 

Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).
Martin B, Chesnel F, Delcros JG, Jouan F, Couturier A, Dugay F, Le Goff X, Patard JJ, Fergelot P, Vigneau C, Rioux-Leclerq N, Arlot-Bonnemains Y
PLoS One. 2013 Jun 

PATENTS

2014 -HASCOET P, CHESNEL F LE GOFF X, COUTURIER A &  ARLOT-BONNEMAINS Y Production d’anticorps monoclonaux dirigés contre la séquence protéique 172 de la proteine VHL humaine. Brevet N° 14305925.1 -1402-reference : BEP :130403EPDP Juin 2014

2015-JOUAN F & ARLOT-BONNEMAINS Y Technologie de  culture organotypique de tissu tumoral  –Mai 2015 – Brevet reference FR 15.53755

Souscrire à notre Newsletter